Apart from Serum, Bharat Biotech, these 5 vaccine makers are India s hope against Covid-19
The current vaccine makers, Serum Institute and Bharat Biotech, alone won t be able to meet the demand. There are other players too in vaccine production, and they should be able to cater to the demand in the months ahead
Manoj Sharma | May 17, 2021 | Updated 11:19 IST
The government has said India will produce a total of 126 crore vaccines between August-December
A crucial part of India s fight against second Covid-19 wave is vaccination. The country has an uphill task to inoculate about 850 million (85 crore) people over the age of 18. It means India will require 1.7 billion vaccines to inoculate the entire lot under the current phase 3. The government has said India will produce a total of 126 crore vaccines between August-December. Over 35.6 crore doses have been either procured or are in the process of procurement. However, the current vaccine makers Serum Institute - the biggest in t
Apart from Serum, Bharat Biotech, these 5 vaccine makers are India s hope against Covid-19
businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.
Synopsis
Despite the over 95 % efficacy of the vaccine, it has to be stored in -18°degrees which could make its administration a tedious task in India where cold storage facilities is a problem.
Sputnik V is based on the human adenovirus vector platform and uses two components of the virus AD 26 and AD5 that needs to be administered 21 days apart.
Dr Reddy’s Laboratories (DRL) will start importing initial doses of Russia’s Sputnik V vaccine this quarter, with India expected to receive 50 million jabs by the end of May. Additional supplies of the vaccine will come after June as Sputnik V’s local manufacturing partners begin production and the logistical issue of storing the vaccine at 2 degree celsius, instead of the current -18 degree centigrade storage temperature is sorted out, DRL CEO, API and services, Deepak Sapru, said on Wednesday.
India gets third Covid-19 vaccine, how it may boost fight against coronavirus pandemic Prabhash K Dutta
India on Monday approved Russian jab Sputnik V as the third Covid-19 vaccine for restricted use in the country. The vaccine was developed by the Gamaleya Research Institute (GRI) of Russia, and funded and promoted outside by the Russian Direct Investment Fund (RDIF).
In India, the RDIF s partner is Dr Reddy s Laboratories, which
conducted clinical trials - mandatory for approval - in India. Sputnik-V became the first vaccine to be announced last year for protection against Covid-19.
It works on a complex biotechnology in which another virus is employed to carry the DNA code required for triggering immune response in human cells. Sputnik V s approval has come at a time when the country is reeling under shortage of existing two vaccines - Covishield and Covaxin.
vimarsana © 2020. All Rights Reserved.